Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

EXEL

Exelixis Inc

Dec 13 • 04:00PM ET

35.03

Dollar change -0.15
Percentage change -0.43	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN AMGN GILD VRTX BIIB BMRN INCY ALNY NBIX IONS

| Held by: IJH VTI VB VXF VBK MDY XBI IBB IJK FBT

Scroll to Statements

Index	-	P/E	22.32	EPS (ttm)	1.57	Insider Own	2.48%	Shs Outstand	285.78M	Perf Week	-2.21%
Market Cap	10.00B	Forward P/E	21.34	EPS next Y	1.64	Insider Trans	-9.42%	Shs Float	278.50M	Perf Month	-0.45%
Income	466.92M	PEG	0.68	EPS next Q	0.39	Inst Own	87.80%	Short Float	3.00%	Perf Quarter	27.52%
Sales	2.08B	P/S	4.81	EPS this Y	154.84%	Inst Trans	2.25%	Short Ratio	3.94	Perf Half Y	61.13%
Book/sh	7.96	P/B	4.40	EPS next Y	-0.91%	ROA	15.73%	Short Interest	8.36M	Perf Year	48.50%
Cash/sh	4.16	P/C	8.41	EPS next 5Y	32.96%	ROE	20.20%	52W Range	19.20 - 36.97	Perf YTD	46.02%
Dividend Est.	-	P/FCF	23.12	EPS past 5Y	-21.77%	ROI	18.90%	52W High	-5.25%	Beta	0.52
Dividend TTM	-	Quick Ratio	3.88	Sales past 5Y	17.31%	Gross Margin	96.25%	52W Low	82.45%	ATR (14)	0.75
Dividend Ex-Date	-	Current Ratio	3.93	EPS Y/Y TTM	462.64%	Oper. Margin	29.22%	RSI (14)	53.75	Volatility	1.67% 2.02%
Employees	1310	Debt/Eq	0.09	Sales Y/Y TTM	17.31%	Profit Margin	22.43%	Recom	1.91	Target Price	32.67
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	12163.64%	Payout	0.00%	Rel Volume	0.71	Prev Close	35.18
Sales Surprise	10.04%	EPS Surprise	17.89%	Sales Q/Q	14.33%	Earnings	Oct 29 AMC	Avg Volume	2.12M	Price	35.03
SMA20	-1.07%	SMA50	7.87%	SMA200	36.00%	Trades		Volume	1,498,290	Change	-0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform	$30 → $34
Sep-19-24	Initiated	UBS	Neutral	$30
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight	$25
Dec-19-23	Initiated	BTIG Research	Buy	$27
Dec-15-23	Initiated	Citigroup	Buy	$31
Sep-26-23	Initiated	H.C. Wainwright	Buy	$28
Aug-22-23	Reiterated	Oppenheimer	Outperform	$25 → $29
Aug-08-23	Initiated	SVB Securities	Market Perform	$18
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight	$21
May-10-23	Resumed	Piper Sandler	Overweight	$28
Mar-09-23	Initiated	Wells Fargo	Overweight	$23
Jan-26-23	Initiated	Credit Suisse	Outperform	$29
Oct-18-22	Initiated	JMP Securities	Mkt Outperform	$26
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28
Nov-19-21	Initiated	Piper Sandler	Overweight	$34
Nov-03-21	Resumed	Jefferies	Buy	$28
Oct-07-21	Initiated	Jefferies	Buy	$28
Aug-06-21	Reiterated	H.C. Wainwright	Buy	$35 → $64
Jun-15-21	Initiated	H.C. Wainwright	Buy	$47
May-18-21	Resumed	Goldman	Sell	$23

Show Previous Ratings

Dec-09-24 12:45PM	Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Dec-07-24 08:45AM	2 Biotech Stocks to Buy Hand Over Fist in December (Motley Fool)
Nov-29-24 09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Nov-28-24 11:31AM	Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-27-24 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December (Business Wire)
04:05PM	Loading…
Nov-26-24 04:05PM	Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors (Business Wire)
Nov-25-24 09:40AM	Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Nov-21-24 12:45PM	3 Reasons Growth Investors Will Love Exelixis (EXEL) (Zacks)
Nov-11-24 02:06PM	Vericel Stock Sees RS Rating Shoot Higher (Investor's Business Daily)
12:00PM	What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now? (Zacks)
09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Nov-07-24 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November (Business Wire)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Nov-05-24 12:45PM	Here is Why Growth Investors Should Buy Exelixis (EXEL) Now (Zacks)
12:20PM	Earnings Estimates Rising for Exelixis (EXEL): Will It Gain? (Zacks)
09:15AM	Loading…
Nov-04-24 09:15AM	Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know (Zacks)
Nov-03-24 06:41AM	3 Magnificent Stocks Under $100 to Buy in November (Motley Fool)
Oct-31-24 07:00PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
07:29AM	Exelixis price target raised to $36 from $33 at Piper Sandler (TipRanks)
Oct-30-24 11:40AM	Q3 2024 Exelixis Inc Earnings Call (Thomson Reuters StreetEvents) +12.91%
03:15AM	Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
02:51AM	Analyst Report: Exelixis, Inc. (Morningstar Research)
12:00AM	Exelixis (EXEL) Q3 2024 Earnings Call Transcript (Motley Fool)
Oct-29-24 06:30PM	Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:20PM	Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:20PM	Exelixis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)
Oct-24-24 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Oct-23-24 12:00PM	Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy (Zacks)
09:53AM	1 No-Brainer Stock to Buy With $40 (Motley Fool)
10:01AM	Loading…
Oct-22-24 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-21-24 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Oct-16-24 11:01AM	Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-24 04:05PM	Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 (Business Wire) +8.61%
01:57PM	Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories (Business Wire)
07:39AM	Exelixis and MSD to trial cancer therapies together in clinical collaboration (Clinical Trials Arena)
Oct-14-24 08:00AM	Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma (Business Wire)
Oct-09-24 08:30AM	ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS (PR Newswire)
Sep-26-24 08:45AM	2 Growth Stocks to Buy With Less Than $100 (Motley Fool)
Sep-20-24 09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Sep-16-24 09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
09:13AM	Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss (Pharmaceutical Technology)
08:45AM	Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine (Business Wire)
Sep-15-24 08:45AM	Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024 (Business Wire)
Sep-14-24 07:39PM	Exelixis, Inc. (EXEL): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-05-24 11:31AM	Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-02-24 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-29-24 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Aug-28-24 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September (Business Wire)
Aug-26-24 12:20PM	Why Exelixis (EXEL) Might be Well Poised for a Surge (Zacks)
Aug-17-24 01:01AM	Insider Sale: Director Maria Freire Sells 8,250 Shares of Exelixis Inc (EXEL) (GuruFocus.com)
Aug-16-24 08:09AM	Exelixis Earnings Drive Share Growth (FX Empire)
Aug-13-24 09:44AM	Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results (Zacks)
Aug-12-24 09:15AM	Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends (Zacks)
Aug-11-24 09:31PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
Aug-09-24 10:28AM	Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review (Investor's Business Daily)
07:35AM	Is Caligan Partners Bullish on Exelixis Inc (EXEL) Right Now? (Insider Monkey)
Aug-07-24 02:29PM	Invenra Highlights Exelixis' Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors (Business Wire) +13.09%
01:30PM	Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues (Zacks)
07:46AM	FDA accepts Exelixis' cabozantinib sNDA for neuroendocrine tumours (Pharmaceutical Business Review)
01:15AM	Exelixis (EXEL) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-06-24 06:30PM	Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:27PM	Exelixis: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)
08:30AM	Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors (Business Wire)
Aug-05-24 09:16AM	What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings (Zacks)
Jul-30-24 10:01AM	Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-23-24 04:05PM	Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 (Business Wire)
Jul-09-24 06:00AM	7 Cheap Biotech Stocks With Major Upside Potential (InvestorPlace)
Jun-27-24 03:28PM	American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond (PR Newswire)
Jun-24-24 09:07PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
Jun-07-24 03:01AM	Insider Sale: Director Jack Wyszomierski Sells Shares of Exelixis Inc (EXEL) (GuruFocus.com)
May-31-24 01:58PM	Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Peconic Partners, Exelixis, Inc. (EXEL), California Resources Corp (CRC), and More (Insider Monkey)
May-30-24 11:31AM	Exelixis (EXEL) Down 6.6% Since Last Earnings Report: Can It Rebound? (Zacks)
May-28-24 04:05PM	Exelixis to Present at the William Blair 44th Annual Growth Stock Conference (Business Wire)
May-24-24 02:34AM	Director Julie Smith Sells 27,280 Shares of Exelixis Inc (EXEL) (GuruFocus.com)
May-21-24 11:20AM	Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla (Zacks)
May-20-24 09:22AM	Exelixis Settles Cabometyx Patent Litigation with Cipla (MT Newswires)
08:00AM	Exelixis Announces Settlement of CABOMETYX (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA (Business Wire)
May-14-24 07:04PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
07:52AM	Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target (MT Newswires)
May-12-24 01:25PM	Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You? (Motley Fool)
May-09-24 03:48PM	Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 10:30AM	Just Say No to Drugs: 3 Pharma Stocks to Avoid (InvestorPlace)
May-07-24 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May (Business Wire)
May-06-24 12:10PM	Exelixis (EXEL) International Revenue Performance Explored (Zacks)
May-03-24 12:21PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
May-02-24 03:33PM	Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-01-24 11:15AM	RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept (MT Newswires) -6.54%
09:14AM	Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short (Zacks)
07:39AM	Q1 2024 Exelixis Inc Earnings Call (Thomson Reuters StreetEvents)
03:35AM	Exelixis Inc (EXEL) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:00AM	Exelixis (EXEL) Q1 2024 Earnings Call Transcript (Motley Fool)
Apr-30-24 08:57PM	EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:30PM	Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:35PM	Exelixis Inc (EXEL) Q1 2024 Earnings: Mixed Results Amidst Restructuring Efforts (GuruFocus.com)
05:26PM	Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours (MT Newswires)
04:19PM	Exelixis: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hessekiel Jeffrey	EVP & General Counsel	Nov 27 '24	Option Exercise	18.80	129,314	2,431,103	644,967	Dec 02 08:29 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 29 '24	Sale	36.67	60,000	2,200,200	486,059	Dec 02 08:29 PM
JEFFREY HESSEKIEL	Officer	Nov 29 '24	Proposed Sale	36.67	60,000	2,200,230		Nov 29 01:12 PM
Haley Patrick J.	EVP, Commercial	Nov 22 '24	Sale	35.27	10,000	352,700	278,665	Nov 26 07:05 PM
PATRICK JOSEPH HALEY	Officer	Nov 22 '24	Proposed Sale	35.27	10,000	352,700		Nov 22 04:01 PM
Haley Patrick J.	EVP, Commercial	Nov 18 '24	Sale	34.36	41,588	1,428,822	288,665	Nov 19 08:03 PM
Haley Patrick J.	Officer	Nov 18 '24	Proposed Sale	34.41	19,381	666,974		Nov 18 06:50 PM
PATRICK JOSEPH HALEY	Officer	Nov 18 '24	Proposed Sale	34.31	22,207	761,884		Nov 18 04:10 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Nov 05 '24	Option Exercise	18.80	96,986	1,823,337	595,931	Nov 07 07:44 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Nov 05 '24	Sale	35.00	96,986	3,394,510	498,945	Nov 07 07:44 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 01 '24	Sale	34.13	50,000	1,706,500	530,325	Nov 05 07:05 PM
POSTE GEORGE	Director	Nov 01 '24	Sale	34.00	30,000	1,020,000	169,020	Nov 05 07:04 PM
DANA T AFTAB	Officer	Nov 05 '24	Proposed Sale	35.00	96,986	3,394,510		Nov 05 04:23 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Oct 30 '24	Sale	31.40	1,162	36,487	498,945	Nov 01 06:43 PM
POSTE GEORGE	Director	Nov 01 '24	Proposed Sale	34.00	30,000	1,020,112		Nov 01 04:54 PM
JEFFREY J HESSEKIEL	Officer	Nov 01 '24	Proposed Sale	33.20	25,000	830,000		Nov 01 04:47 PM
Hessekiel Jeffrey	EVP & General Counsel	Oct 28 '24	Sale	28.39	25,000	709,750	580,325	Oct 30 06:04 PM
DANA T AFTAB	Officer	Oct 30 '24	Proposed Sale	31.40	1,162	36,487		Oct 30 04:10 PM
Haley Patrick J.	EVP, Commercial	Oct 02 '24	Option Exercise	24.41	100,000	2,441,000	441,036	Oct 03 09:22 PM
MORRISSEY MICHAEL	President and CEO	Oct 01 '24	Option Exercise	24.41	480,000	11,716,800	1,444,384	Oct 03 09:22 PM
Hessekiel Jeffrey	EVP & General Counsel	Sep 23 '24	Sale	26.38	25,000	659,500	605,325	Sep 25 07:32 PM
JEFFREY J HESSEKIEL	Officer	Sep 23 '24	Proposed Sale	26.42	75,000	1,981,500		Sep 23 04:24 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 26 '24	Option Exercise	24.41	20,000	488,200	650,325	Aug 28 07:07 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 26 '24	Sale	25.79	20,000	515,800	630,325	Aug 28 07:07 PM
Freire Maria C	Director	Aug 14 '24	Sale	26.56	8,250	219,120	91,007	Aug 16 07:35 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 12 '24	Sale	27.06	20,883	565,094	500,107	Aug 14 07:12 PM
MARIA C FREIRE	Director	Aug 14 '24	Proposed Sale	26.56	8,250	219,122		Aug 14 05:01 PM
POSTE GEORGE	Director	Aug 08 '24	Sale	26.89	33,725	906,865	199,020	Aug 12 07:22 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 07 '24	Option Exercise	24.41	95,000	2,318,950	615,990	Aug 09 07:32 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 07 '24	Sale	25.00	95,000	2,375,000	520,990	Aug 09 07:32 PM
Haley Patrick J.	EVP, Commercial	Aug 07 '24	Sale	25.50	14,000	357,000	341,036	Aug 09 07:32 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 07 '24	Option Exercise	24.41	80,000	1,952,800	710,325	Aug 09 07:32 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 07 '24	Sale	25.97	80,000	2,077,600	630,325	Aug 09 07:32 PM
Senner Christopher J.	EVP and CFO	Aug 09 '24	Option Exercise	24.41	125,000	3,051,250	846,680	Aug 09 07:31 PM
Senner Christopher J.	EVP and CFO	Aug 09 '24	Sale	27.19	125,000	3,398,750	721,680	Aug 09 07:31 PM
Senner Christopher J.	Officer	Aug 09 '24	Proposed Sale	27.17	125,000	3,396,250		Aug 09 05:20 PM
Aftab Dana	Officer	Aug 09 '24	Proposed Sale	27.25	20,883	569,062		Aug 09 05:18 PM
POSTE GEORGE	Director	Aug 08 '24	Proposed Sale	26.89	33,725	906,746		Aug 08 05:42 PM
DANA T AFTAB	Officer	Aug 07 '24	Proposed Sale	25.00	95,000	2,375,000		Aug 07 04:17 PM
JEFFREY J HESSEKIEL	Officer	Aug 07 '24	Proposed Sale	23.45	100,000	2,345,000		Aug 07 04:13 PM
PATRICK JOSEPH HALEY	Officer	Aug 07 '24	Proposed Sale	25.50	14,000	357,000		Aug 07 04:11 PM
WYSZOMIERSKI JACK L	Director	Jun 04 '24	Sale	22.00	8,287	182,314	349,499	Jun 06 08:37 PM
JOHNSON DAVID EDWARD	Director	May 30 '24	Buy	20.76	225,000	4,670,055	1,525,730	May 30 07:50 PM
JOHNSON DAVID EDWARD	Director	May 28 '24	Buy	20.32	200,000	4,063,900	1,300,730	May 30 07:50 PM
Smith Julie	Director	May 21 '24	Sale	21.12	27,280	576,154	5,445	May 23 06:55 PM
POSTE GEORGE	Director	May 21 '24	Option Exercise	19.57	11,686	228,695	225,593	May 22 07:23 PM
POSTE GEORGE	Director	May 21 '24	Sale	20.96	11,686	244,939	213,907	May 22 07:23 PM
PAPADOPOULOS STELIOS	Director	May 20 '24	Option Exercise	19.57	11,686	228,695	1,272,015	May 22 07:23 PM
PAPADOPOULOS STELIOS	Director	May 20 '24	Sale	21.00	11,437	240,177	1,260,578	May 22 07:23 PM
WYSZOMIERSKI JACK L	Director	May 13 '24	Option Exercise	19.57	11,686	228,695	349,871	May 15 07:44 PM
WYSZOMIERSKI JACK L	Director	May 13 '24	Sale	21.37	10,923	233,425	338,948	May 15 07:44 PM
Garber Alan M	Director	Mar 21 '24	Option Exercise	19.57	23,491	459,719	54,908	Mar 25 07:31 PM
Garber Alan M	Director	Mar 21 '24	Sale	24.01	19,205	461,112	35,703	Mar 25 07:31 PM
Haley Patrick J.	EVP, Commercial	Feb 23 '24	Sale	21.45	47,020	1,008,579	384,866	Feb 27 06:58 PM
JOHNSON DAVID EDWARD	Director	Feb 21 '24	Buy	20.70	190,000	3,932,734	1,100,730	Feb 22 05:08 PM
Haley Patrick J.	EVP, Commercial	Dec 14 '23	Option Exercise	16.29	50,000	814,500	357,687	Dec 14 07:56 PM
Haley Patrick J.	EVP, Commercial	Dec 14 '23	Sale	23.35	50,000	1,167,500	307,687	Dec 14 07:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EXEL

Exelixis Inc

Upgrade your FINVIZ experience